Revolutionising Pharma with Enterprise Data and AI
In today’s dynamic pharmaceutical landscape, the race to innovate while maintaining regulatory compliance and operational efficiency is more challenging than ever.
Our Enterprise Data & AI services are tailored to meet these challenges head-on offering;
Predictive Analytics: Anticipate market trends, patient needs, and drug efficacy outcomes.
Operational Efficiency: Streamline processes, reduce costs, and enhance productivity.
Regulatory Compliance: Ensure adherence to global standards through intelligent data governance.
Customised Solutions: From R&D to supply chain optimisation, our solutions are designed to cater to your unique needs.
We understand the pain points of managing vast data silos, the complexity of regulatory environments, and the pressure of staying ahead in innovation. Our services are crafted to address these challenges, ensuring that your data not only complies but propels you forward.
Introducing VaxLens Service
From Data to Narrative:
A dedicated service to pharmaceutical policy teams that supports strategies to maximise vaccine market access, by defining and demonstrating vaccine value.
VaxLens Service by OpenSky is our bespoke service specifically developed for the pharmaceutical sector. VaxLens represents a paradigm shift in vaccine management and distribution, offering unparalleled insights and operational control.
Learn more about how VaxLens can transform your vaccine lifecycle management
Success Spotlight - VaxLens in Action at MSD Pharmaceuticals
VaxLens has already paved the way for groundbreaking advancements in the industry.
At MSD Pharmaceuticals, our collaboration has led to:
Enhanced vaccine distribution efficiency.
Improved inventory management.
Real-time data insights for better decision-making.
About the Research & the Report
MSD commissioned OpenSky to conduct and complete a Research report which would outline the correlation between the existence of evolved EVRs (Electronic Vaccination Registries) and higher Vaccine Coverage Rates (VCRs) in the EU, the UK, Norway, Switzerland and Serbia.
Using the HPV Vaccination as a case study, the research commenced in November 2021 and continued into Q2 2022, capturing in-depth data from every country and delivering a heatmap & scoreboard to visualise the correlation between EVRs and VCRs.
.png?width=200&height=200&name=VaxLens%20Logo%20(1).png "VaxLens Logo (1)")
